Sanofi to cut price of its most-prescribed insulin by 78% in US

Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, starting next year after a similar move by rivals Novo Nordisk and Eli Lilly and Co. The French drugmaker will also set a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance.

Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, starting next year after a similar move by rivals Novo Nordisk and Eli Lilly and Co.

The French drugmaker will also set a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance. The move comes as U.S. President Joe Biden has pushed to extend to most Americans the $35 cap on out-of-pocket insulin costs made available to Medicare recipients by the Inflation Reduction Act.

Sanofi will also cut the list price for a type of fast-acting insulin, Apidra, by 70%, that helps to lower blood sugar levels in patients with type 1 and type 2 diabetes. Novo Nordisk and Eli Lilly bowed to political pressure earlier this month to make these life-sustaining diabetes treatments more affordable.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)